ERBB3 and breast cancer: Treatment of HER2-amplified breast cancers with HER2-targeting tyrosine kinase inhibitors (TKIs) promotes an increase in HER3 plasma membrane localization and downstream signaling, which can lead to resistance to the HER2-targeted therapies [9–11].